Searching the RRID Resource Information Network
Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.
SciCrunch Registry is a curated repository of scientific resources, with a focus on biomedical resources, including tools, databases, and core facilities - visit SciCrunch to register your resource.
| Resource Name | Proper Citation | Abbreviations | Resource Type |
Description |
Keywords | Resource Relationships | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Ovation Resource Report Resource Website 1+ mentions |
Ovation (RRID:SCR_003737) | Ov | commercial organization, data management software, software application, software resource | A dropbox like model cloud-based, commercial data management and collaboration system designed specifically for research scientists. It helps manage and annotate data, track provenance and share this with colleagues. | cloud based | Free trial, Commercial | SciRes_000172, nlx_158031 | SCR_003737 | SciCrunch Registry | 2026-09-26 02:13:32 | 3 | |||||||||
|
Mouse Gross Anatomy and Development Ontology Resource Report Resource Website |
Mouse Gross Anatomy and Development Ontology (RRID:SCR_003891) | EMAP | controlled vocabulary, data or information resource, ontology | A structured controlled vocabulary of stage-specific anatomical structures of the mouse (Mus). | obo | is listed by: BioPortal | nlx_157488 | SCR_003891 | SciCrunch Registry | 2026-09-26 02:13:34 | 0 | |||||||||
|
PEAR Resource Report Resource Website 500+ mentions |
PEAR (RRID:SCR_003776) | PEAR | software resource | Software for an ultrafast, memory-efficient and highly accurate pair-end read merger. It is fully parallelized and can run with as low as just a few kilobytes of memory. | next-generation sequencing, sequence analysis |
is listed by: OMICtools has parent organization: Heidelberg Institute for Theoretical Studies; Heidelberg; Germany |
PMID:24142950 | OMICS_00674 | SCR_003776 | SciCrunch Registry | Pair-end read merger, PEAR: Pair-end read merger | 2026-09-26 02:13:35 | 914 | |||||||
|
Pharmatching Resource Report Resource Website |
Pharmatching (RRID:SCR_003897) | Pharmatching | catalog, commercial organization, community building portal, data or information resource, database, portal, service resource | A matchmaker portal for the pharmaceutical industry worldwide offering a directory and contact platform. This includes a database of ten thousands of profiles of companies offering pharma services as well as a selection of companies including niche providers delivering the service of interest. The platform is used to search for human medicinal products, veterinary medicinal products, cosmeceuticals, nutriceuticals, medical devices, and diagnostics. The company''s platform also enables users to post their service requests, service offers, and APIs/intermediates; and interact with other users. In addition, it offers advice and operational support services for outsourcing and inlicensing processes, such as strategic, scientific, and regulatory advice related to due diligence and decision making of research and development, sourcing, and M and A processes; conduct of third party GMP and pharmacovigilance audits; customized interim solutions; and qualified person functions for GMP and pharmacovigilance. The company also serves various sectors of the life science industry, such as contract manufacture, laboratory investigations and contractual testing, clinical research organizations and pre-clinical research organizations, consulting and legal counseling, logistics and distribution, education, marketing, IT, and investment and financing sectors; and small and medium enterprises/pharma, academic, public institutions, and freelancers. (Bloomberg Businessweek) | outsourcing, pharmaceutical, biotechnology, human medicine, biopharmaceutical, medical device, cosmeceutical, nutraceutical | is related to: ONE Study | The community can contribute to this resource | nlx_158230 | SCR_003897 | SciCrunch Registry | Pharmatching.com, Pharmatching GmbH | 2026-09-26 02:13:37 | 0 | |||||||
|
Lhasa Limited Resource Report Resource Website 10+ mentions |
Lhasa Limited (RRID:SCR_003775) | Lhasa | community building portal, data or information resource, funding resource, portal, software resource | A not-for-profit membership organization and educational charity that facilitates collaborative data sharing projects in the pharmaceutical, cosmetics and chemistry-related industries specializing in the development of expert computer systems for toxicity and metabolism prediction. They provide a number of extensive and continually updated knowledge bases and the software needed to interrogate them. Its charitable aims include the sponsorship of activities that advance scientific knowledge and understanding and they regularly support computational chemistry events and initiatives that are of interest to Lhasa Limited members and the wider scientific community. All applications for sponsorship will be considered on their individual merits. | data sharing, pharmaceutical, cosmetic, chemistry, toxicity prediction, metabolism, toxicity, metabolism prediction, prediction, database, in silico, computational chemistry, computer system | is related to: MIP-DILI | Membership required, For sale | nlx_158058 | SCR_003775 | SciCrunch Registry | Lhasa Ltd. | 2026-09-26 02:13:32 | 17 | |||||||
|
Electro Scientific Industries Resource Report Resource Website |
Electro Scientific Industries (RRID:SCR_003895) | ESI | commercial organization | A high technology company that is a developer and supplier of photonic and laser systems for microelectronics manufacturers. They manufacture a variety of products for testing and repairing equipment, and particularly products designed for use by manufacturers of other high-tech products. These include laser trimming systems. (Adapted from Wikipedia) | microengineering, electronics, semiconductor, testing, repair, laser trimming system, photonic, laser, microelectronics | is related to: ONE Study | nlx_158228 | SCR_003895 | SciCrunch Registry | Electro Scientific Industries Inc. | 2026-09-26 02:13:34 | 0 | ||||||||
|
IAESTE Resource Report Resource Website |
IAESTE (RRID:SCR_003773) | IAESTE | training resource | An independent, non-profit and non-political student exchange organization that provides students in technical degrees (primarily Science, Engineering and the applied arts) with paid, course-related, training abroad and employers with highly skilled, highly motivated trainees, for long or short term projects. | student, international | has parent organization: Imperial College London; London; United Kingdom | nlx_158047 | SCR_003773 | SciCrunch Registry | International Association for the Exchange of Students for Technical Experience | 2026-09-26 02:13:32 | 0 | ||||||||
|
TRANSFoRm Clinical Research Information Model Resource Report Resource Website |
TRANSFoRm Clinical Research Information Model (RRID:SCR_003889) | CRIM | data or information resource, narrative resource, report, standard specification | A clinical research information model for the integration of clinical research covering randomized clinical trials (RCT), case-control studies and database searches into the TRANSFoRm application development. TRANSFoRm clinical research is based on primary care data, clinical data and genetic data stored in databases and electronic health records and employs the principle of reusing primary care data, adapting data collection by patient reported outcomes (PRO) and eSource based Case Report Forms. CRIM was developed using the TRANSFoRm clinical use cases of GORD and Diabetes. Their use case driven approach consisted of three levels of modelling drawing heavily on the clinical research workflow of the use cases. Different available information models were evaluated for their usefulness to represent TRANSFoRm clinical research, including for example CTOM of caBIG, Primary Care Research Object Model (PRCOM) of ePCRN and BRIDG of CDISC. The PCROM model turned out to be the most suitable and it was possible to extend and modify this model with only 12 new information objects, 3 episode of care related objects and 2 areas to satisfy all requirements of the TRANSFoRm research use cases. Now the information model covers Good Clinical Practice (GCP) compliant research, as well as case control studies and database search studies, including the interaction between patient and GP (family doctor) during patient consultation, appointment, screening, patient recruitment and adverse event reporting. | clinical, randomized clinical trial, clinical trial, primary care, genetic, clinical research, electronic health record, model, interoperability |
uses: Clinical Data Interchange Standards Consortium is used by: TRANSFoRm Data Integration Models has parent organization: TRANSFoRm |
nlx_158219 | SCR_003889 | SciCrunch Registry | Clinical Research Information Model | 2026-09-26 02:13:34 | 0 | ||||||||
|
OncoTrack Resource Report Resource Website 1+ mentions |
OncoTrack (RRID:SCR_003767) | OncoTrack | consortium, data or information resource, organization portal, portal | An international consortium to develop and assess novel approaches to identify and characterize biological markers for colon cancer that will deepen the understanding of the variable make-up of tumors and how this affects the way patients respond to treatment. They will use cutting edge laboratory-based genome sequencing techniques coupled to novel computer modelling approaches to study both the biological heterogeneity of colon cancers (i.e. patient to patient variability) as well as tumor variation within the patient for example, by comparing primary tumors with metastases. This five year project brings together top scientists from European academic institutions offering a wide range of expertise, and partners them with pharmaceutical companies. The project is based on the premise that this genetic and epigenetic information, combined with a description of the molecular pathology of the tumor, will allow OncoTrack to generate a more accurate in-silico model of the cancer cell. This will facilitate the identification of predictive markers that can be used to guide the optimal therapy strategy at the level of the individual patient - and will also provide on-going prognostic guidance for the clinician. This project will not only advance understanding of the fundamental biology of colon cancers but will provide the means and approach for the identification of previously undetected biomarkers not only in the cancer under study, but potentially also in other solid cancers and, in doing so, open the door for personalized management of the oncology patient. | oncology, biomarker, diagnosis, basic science, genome sequencing, computer modelling, genetic, epigenetic, pathology, model, cancer cell, colon, cancer, treatment, genomics, clinical, systems biology, in-silico model, patient variability, tumor variability |
uses: GenomeWeb uses: eTRIKS is listed by: Consortia-pedia is related to: Roche is related to: Janssen Research and Development is related to: Merck is related to: Pfizer Animal Genetics is related to: Charite - Universitatsmedizin Berlin; Berlin; Germany is related to: Max Planck Institute for Molecular Genetics; Berlin; Germany is related to: Medical University of Graz; Graz; Austria is related to: Paris-Sud University; Paris; France is related to: Dresden University of Technology; Saxony; Germany is related to: University College London; London; United Kingdom is related to: Uppsala University; Uppsala; Sweden is related to: Stockholm University; Stockholm; Sweden is related to: Vall d'Hebron Institute of Oncology; Barcelona; Spain is related to: Alacris Theranostics is related to: Experimental Pharmacology and Oncology Berlin-Buch is related to: GABO:mi is related to: International Prevention Research Institute has parent organization: Max Planck Institute for Molecular Genetics; Berlin; Germany |
Innovative Medicines Initiative ; EFPIA |
nlx_158037 | SCR_003767 | SciCrunch Registry | OncoTrack - Methods for systematic next generation oncology biomarker development, Onco Track | 2026-09-26 02:13:32 | 9 | |||||||
|
TRANSFoRm Resource Report Resource Website 50+ mentions |
TRANSFoRm (RRID:SCR_003888) | TRANSFoRm | consortium, data or information resource, organization portal, portal | Project to develop a ''rapid learning healthcare system'' driven by advanced computational infrastructure that can improve both patient safety and the conduct and volume of clinical research in Europe. Three carefully chosen clinical ''use cases'' will drive, evaluate and validate the approach to the ICT (information and communications technology) challenges. The project will build on existing work at international level in clinical trial information models (BRIDG and PCROM), service-based approaches to semantic interoperability and data standards (ISO11179 and controlled vocabulary), data discovery, machine learning and electronic health records based on open standards (openEHR). TRANSFoRm will extend this work to interact with individual eHR systems as well as operate within the consultation itself providing both diagnostic support and support for the identification and follow up of subjects for research. The approach to system design will be modular and standards-based, providing services via a distributed architecture, and will be tightly linked with the user community. Four years of development and testing will end with a fifth year that will be dedicated to summative validation of the project deliverables in the Primary Care setting. In order to support patient safety in both clinical and research settings, significant ICT challenges need to be overcome in the areas of interoperability, common standards for data integration, data presentation, recording, scalability, and security., THIS RESOURCE IS NO LONGER IN SERVICE. Documented on September 16,2025. | clinical, interoperability, healthcare system, healthcare, electronic health record, clinical data, metadata standard, aggregator |
has parent organization: King's College London; London; United Kingdom is parent organization of: TRANSFoRm Clinical Data Integration Model is parent organization of: TRANSFoRm Clinical Research Information Model is parent organization of: TRANSFoRm Data Integration Models |
European Union FP7 247787 | THIS RESOURCE IS NO LONGER IN SERVICE | nlx_158218 | SCR_003888 | SciCrunch Registry | Translational Research and Patient Safety In Europe | 2026-09-26 02:13:37 | 60 | ||||||
|
Predict-TB Resource Report Resource Website 10+ mentions |
Predict-TB (RRID:SCR_003766) | PreDiCT-TB | consortium, data or information resource, organization portal, portal | Consortium to accelerate the search for new, more effective combinations of treatments to tackle Tuberculosis and address pre-clinical research barriers to the discovery and development of new TB drug combinations. To overcome the challenges in Tuberculosis drug development they will create tools to accelerate PK-PD (Pharmacokinetic / Pharmacodynamic) analysis that are connected to clinical outcomes. By addressing the gaps in preclinical information, the consortium aims to provide a framework and tools to facilitate the transition of the best combinations of drugs to late phase development. They aim to develop an integrated set of laboratory-based models that will provide much-needed data to indicate the most appropriate doses and combinations of drugs for patients. In addition, the project will generate a comprehensive database of patient data from previous and on-going clinical trials for use as a reference for evaluating the performance of combination anti-TB drug regimens in these newly developed laboratory models. Ultimately, they aim to enable researchers to be able to use the information generated by the novel models to design better clinical trials involving TB patients. The aims of the consortium: * To systematically evaluate two successive panels of representative anti-tuberculosis drugs (licensed and novel) using a suite of standard, novel and enhanced preclinical model systems, with respect to performance in clinical trials * To refine the set of preclinical systems on the basis of these results in order to identify and define the currently optimal critical path in discovery and pre-clinical development for tuberculosis. * To develop an integrated PK-PD / Disease modelling and simulation framework for tuberculosis which will facilitate prediction of optimal combinations and design of clinical studies. | pre-clinical, drug, bedaquiline, tool development, basic research, drug development, lung, model, simulation, database |
uses: eTRIKS is listed by: Consortia-pedia is related to: Critical Path to TB Drug Regimens is related to: Janssen Research and Development is related to: University of Liverpool; Liverpool; United Kingdom is related to: Ecole Polytechnique Federale de Lausanne; Lausanne; Switzerland is related to: Public Health England; London; United Kingdom is related to: Pasteur Institute is related to: Liverpool School of Tropical Medicine; Liverpool; United Kingdom is related to: Max-Planck-Gesellschaft is related to: St Georges University of London; London; United Kingdom is related to: Charles III University of Madrid; Madrid; Spain is related to: University College London; London; United Kingdom is related to: University of Leicester; Leicester; United Kingdom is related to: University of St Andrews; Scotland; United Kingdom is related to: Uppsala University; Uppsala; Sweden is related to: Microsens is related to: ZF-screens is related to: Max Planck Institute for Infection Biology; Berlin; Germany is related to: Max Planck Institute of Molecular Cell Biology and Genetics; Dresden; Germany is related to: University of Sussex; Brighton; United Kingdom has parent organization: University of Liverpool; Liverpool; United Kingdom |
Innovative Medicines Initiative 115337; EFPIA |
nlx_158036 | SCR_003766 | SciCrunch Registry | PreDiCT - TB | 2026-09-26 02:13:34 | 10 | |||||||
|
Stein Institute for Research on Aging Video Archive Resource Report Resource Website 1+ mentions |
Stein Institute for Research on Aging Video Archive (RRID:SCR_003761) | Stein Institute Videos | data or information resource, narrative resource, podcast, video resource | Videos and podcasts presenting the latest innovative research being conducted by the Stein Institute for Research on Aging medical faculty, with the aim of promoting healthy aging. Additionally, many of the public lectures from the Public Lecture Series are also available on UCSD-TV's website video on demand programming. The Lecture series allows affiliated faculty members of the Stein Institute for Research on Aging and other scientists from the UCSD School of Medicine, as well as individuals from surrounding academic and research institutions, to present the latest findings in their respective fields of expertise and share their present work with the general community. All of these lectures focus on topics related to healthy aging or age-related diseases. | late adult human |
uses: UCSD-TV has parent organization: Stein Institute for Research on Aging |
Aging, Healthy aging, Age-related disease | Public, Commercial license | nlx_157990 | SCR_003761 | SciCrunch Registry | 2026-09-26 02:13:34 | 1 | |||||||
|
eTRIKS Resource Report Resource Website 10+ mentions |
eTRIKS (RRID:SCR_003765) | eTRIKS | consortium, data or information resource, organization portal, portal, service resource | Research informatics and analytics platform for the IMI OncoTrack consortium. | data sharing, drug discovery, translational research, informatics, knowledge management, metadata standard, platform, analytics, tool development, bio.tools |
uses: tranSMART is used by: U-BIOPRED is used by: Predict-TB is used by: OncoTrack is used by: ABIRISK is used by: RA MAP is listed by: Consortia-pedia is listed by: Debian is listed by: bio.tools is related to: Roche is related to: Janssen Research and Development is related to: Merck is related to: Pfizer Animal Genetics is related to: Imperial College London; London; United Kingdom is related to: French National Center for Scientific Research is related to: Clinical Data Interchange Standards Consortium is related to: University of Luxembourg; Luxembourg; Luxembourg is related to: IDBS is related to: BioSci Consulting is related to: TraIT is related to: EMIF is related to: Open PHACTS has parent organization: Imperial College London; London; United Kingdom |
Innovative Medicines Initiative ; EFPIA |
PMID:29482119 | biotools:eTRIKS, nlx_158034 | https://bio.tools/eTRIKS | SCR_003765 | SciCrunch Registry | European Translational Information and Knowledge Management Services, European Translational Information & Knowledge Management Services | 2026-09-26 02:13:32 | 11 | |||||
|
mzML Resource Report Resource Website 10+ mentions |
mzML (RRID:SCR_003763) | mzML | data or information resource, interchange format, markup language, narrative resource, standard specification | Markup language for encoding raw spectrometer output. From 2005-2008 there has existed two separate XML formats for encoding raw spectrometer output: mzData developed by the PSI and mzXML developed at the Seattle Proteome Center at the Institute for Systems Biology. It was recognized that the existence of two separate formats for essentially the same thing generated confusion and required extra programming effort. Therefore the PSI, with full participation by ISB, has developed a new format by taking the best aspects of each of the precursor formats to form a single one. It is intended to replace the previous two formats. This new format was originally given a working name of dataXML. The final name is mzML. | mass spectrometry, specification |
is used by: Mspire-Simulator is related to: pymzML has parent organization: HUPO Proteomics Standards Initiative |
nlx_158004 | SCR_003763 | SciCrunch Registry | mzML Specification | 2026-09-26 02:13:32 | 24 | ||||||||
|
PREDECT Resource Report Resource Website 1+ mentions |
PREDECT (RRID:SCR_003883) | PREDECT | consortium, data or information resource, organization portal, portal | Project that aims to create more appropriate in vitro platforms for target validation and drug discovery for breast, prostate and lung cancers. Laboratory platforms to validate whether target modulation would provide a clinical benefit are usually highly reductionist, often using long-established cell lines growing in 2 dimensions in vitro. These models do not reflect the complexity and heterogeneity of a tumor in situ, where biochemical pathways are wired with connections to the complex tumor environment provided by the stroma. PREDECT has the goal of comparing the pathological and molecular profiles of novel in vitro platforms with those of human tumors. Because obtention of clinical material presents both logistics and quality problems for ongoing and intense studies of target validation, PREDECT aims to use material from genetically engineered mouse models, and some advanced xenografts, whose pathology and molecular profiles closely match cohorts of human tumors. PREDECT hopes to provide more appropriate in vitro platforms both for target validation and subsequent preclinical studies which will replace a current cascade of tests which are poorly predictive of clinical activity. The project is expected to shift paradigms in cell biology as well as in preclinical target validation where it should permit greater predictivity of drug efficacy in patient cohorts. | drug, oncology, drug development, basic research, in vitro, xenograft, breast, prostate, lung, pre-clinical, target validation, drug discovery |
is listed by: Consortia-pedia is related to: Roche is related to: Orion is related to: sigma-tau is related to: Janssen Research and Development is related to: AbbVie is related to: Institute of Cancer Research is related to: Ecole Polytechnique Federale de Lausanne; Lausanne; Switzerland is related to: VTT Technical Research Centre of Finland is related to: University of Helsinki; Helsinki; Finland is related to: University of Tartu; Tartu; Estonia is related to: Biomedicum Genomics is related to: Oncotest is related to: Institute of Experimental Biology and Technology; Oeiras; Portugal is related to: Cardiff University; Wales; United Kingdom has parent organization: University of Helsinki; Helsinki; Finland |
Innovative Medicines Initiative ; EFPIA |
nlx_158212 | SCR_003883 | SciCrunch Registry | Preclinical evaluation of drug efficacy in common solid tumours, Predect New models for preclinical evaluation of drug efficacy in common solid tumours | 2026-09-26 02:13:37 | 8 | |||||||
|
TI Pharma Resource Report Resource Website 10+ mentions |
TI Pharma (RRID:SCR_003758) | TI Pharma | consortium, data or information resource, funding resource, organization portal, portal | A not-for-profit organization that initiates and manages drug development consortia that involve the pharmaceutical industry, academia, and the Dutch Government. The aim of all their consortia is to conduct pre-competitive research while strengthening the Netherlands' international reputation for drug development. The consortia are focused on addressing therapeutic areas that are listed as priority areas by the World Health Organization including: autoimmune diseases, cardiovascular diseases, cancer, infectious diseases, and diseases of the brain. The consortia are also focused on enabling: therapeutic target discovery, validation, and animal models; lead selection and in-silico modeling; predictive drug disposition and toxicology; biomarkers and biosensors; drug formulation, delivery, and targeting; and, production technologies. TI Pharma consortia aim to improve the efficiency of the drug-development process, with a focus on advancing regulatory science. In addition to research, TI Pharma also has objectives to train and educate scientists in the Netherlands on the drug discovery and development processes, as well as on entrepreneurship. Participants include: all Dutch universities and academic medical centers, more than 30 industrial partners, small-to-medium sized companies, and representatives from the Dutch Medicines Evaluation Board (Netherlands regulatory body for drugs). | consortium, biomarker, drug, drug development, tool development, pharmaceutics, drug discovery, animal model, biosensor, drug formulation, drug delivery, drug target, medicine |
is listed by: Consortia-pedia is related to: European Lead Factory is related to: Kinetics for Drug Discovery is parent organization of: Towards novel translational safety biomarkers for adverse drug toxicity is parent organization of: European Lead Factory is parent organization of: Kinetics for Drug Discovery |
Dutch government ; industry ; academia |
nlx_157987 | SCR_003758 | SciCrunch Registry | Stichting Top Instituut Pharma, Top Industry Pharma, Top Institute Pharma, Foundation Top Institute Pharma | 2026-09-26 02:13:32 | 12 | |||||||
|
PyroBayes Resource Report Resource Website 1+ mentions |
PyroBayes (RRID:SCR_003757) | PyroBayes | software resource | THIS RESOURCE IS NO LONGER IN SERVICE. Documented on January 6, 2023. A base caller for pyrosequences from the 454 Life Sciences sequencing machines. | is listed by: OMICtools | PMID:18193056 | THIS RESOURCE IS NO LONGER IN SERVICE | OMICS_01155 | SCR_003757 | SciCrunch Registry | 2026-09-26 02:13:32 | 3 | ||||||||
|
PharmaCog Resource Report Resource Website 10+ mentions |
PharmaCog (RRID:SCR_003878) | PharmaCog | consortium, data or information resource, organization portal, portal | Project aiming to tackle bottlenecks in Alzheimer''''s disease research and drug discovery by developing and validating new tools to test candidate drugs for the treatment of symptoms and disease in a faster and more sensitive way. They will provide the tools needed to define more precisely the potential of a drug candidate, reduce the development time of new medicines and thus accelerate the approvals of promising new medicines. By bringing together databases of previously conducted clinical trials and combining the results from blood tests, brain scans and behavioral tests, the scientists will develop a ''''signature'''' that gives more accurate information on the progression of the disease and the effect of candidate drugs than current methods do. The scientists will conduct parallel studies in laboratory models, healthy volunteers and patients in order to better predict good new drugs as early as possible. This will enable them, for instance, to find out how memory loss in Alzheimer''''s disease can be simulated in healthy volunteers, for example with sleep deprivation or drugs that temporarily affect the memory, in order to test the effect of candidate-medicines early in the drug development process. | drug, biomarker, drug discovery, model, tool development, drug development, medicine, clinical, pre-clinical, pharmacology, disease progression, cognitive impairment |
is listed by: Consortia-pedia is related to: Merck is related to: Janssen Research and Development is related to: Roche is related to: Eisai is related to: Aix-Marseille University; Provence-Alpes-Cote d'Azur; France is related to: Alzheimer Europe is related to: French National Center for Scientific Research is related to: Greek Association of Alzheimers Disease and Related Disorders is related to: August Pi i Sunyer Biomedical Research Institute; Barcelona; Spain is related to: National Institute of Health and Medical Research; Rennes; France is related to: Mario Negri Institute for Pharmacological Research; Milan; Italy is related to: University of Murcia; Murcia; Spain is related to: Catholic University of the Sacred Heart; Milan; Italy is related to: University of Foggia; Foggia; Italy is related to: University of Genoa; Genoa; Italy is related to: University of Perugia; Perugia; Italy is related to: University of Verona; Verona; Italy is related to: University of Leipzig; Saxony; Germany is related to: Lille 2 University of Health and Law; Lille; France is related to: University of Exeter; Exeter; United Kingdom is related to: Innovative Concepts in Drug Development is related to: AlzProtect is related to: Qualissima is related to: Exonhit Therapeutics is related to: University of Bristol; Bristol; United Kingdom is related to: European Medicines Agency has parent organization: Lille 2 University of Health and Law; Lille; France has parent organization: Alzheimer Europe has parent organization: Aix-Marseille University; Provence-Alpes-Cote d'Azur; France |
Innovative Medicines Initiative 115009; EFPIA |
nlx_158206 | SCR_003878 | SciCrunch Registry | Prediction of cognitive properties of new drug candidates for neurodegenerative diseases in early clinical development, Pharma-Cog | 2026-09-26 02:13:34 | 13 | |||||||
|
Oxford Nanopore Technologies Resource Report Resource Website 100+ mentions |
Oxford Nanopore Technologies (RRID:SCR_003756) | Oxford Nanopore | commercial organization | Commercial organization developing a disruptive, proprietary technology platform for the direct, electronic analysis of single molecules. The instruments GridION and MinION are adaptable for the analysis of DNA, RNA, proteins, small molecules and other types of molecule. Consequently, the platform has a broad range of potential applications, including scientific research, personalized medicine, crop science and security / defence. | nanopore technology, dna, rna, protein, small molecule, molecule, analysis, nanopore, nanopore sensing |
is related to: READNA is related to: Pychopper |
nlx_158233 | SCR_003756 | SciCrunch Registry | Oxford Nanopore Technologies Ltd | 2026-09-26 02:13:34 | 448 | ||||||||
|
Patients to Trials Consortium Resource Report Resource Website |
Patients to Trials Consortium (RRID:SCR_003877) | Patients2Trials Consortium | community building portal, consortium, data or information resource, organization portal, people resource, portal, service resource | A three-member pharmaceutical industry consortium that aims to provide a new platform to improve access to information about clinical trials for patients and providers. The platform aims to enhance the existing clinicaltrials.gov by providing more detailed and patient-friendly information about available trials and embedding a machine-readable target health profile to improve the ability of healthcare software to match individual health profiles with applicable clinical trials. Using clinicaltrials.gov as its foundation and Eli Lilly''''s Application Programming Interface (API), the consortium is focused on creating an open platform to make this data more amenable to patients and providers, as well as creating an opportunity to integrate a patient''''s electronic health record into the clinical trial matching service. This feature will allow patients to search for trials using their own Blue Button data. The following features are planned add-ons to clinicaltrials.gov: * Target Profile is a machine readable query, that can be executed against an electronic file (or record) with patient health data such as an Electronic Health Record (EHR), an Electronic Medical Record (EMR) or Personally Controlled Health Record (PCHR) * Augmented Content is public, IRB approved information about the study that has not been published on clinicaltrials.gov, and that is shared with / targeted for patients with a matching Target Profile. The following are the incremental goals of the consortium: * Advancement of the Lilly API platform to support read/write interaction and additional data objects and information. * The initial 3 sponsor organizations - Lilly, Pfizer and Novartis - will upload Target Profiles for a select set of clinical trials. A Target Profile is a machine interpretable description of the characteristics of patients who may qualify for that trial i.e. a query that can be executed against a patient''''s electronic health record or personal health record. Additionally, sponsors of clinical research studies will also be able to upload Augmented Content to the Lilly Platform to supplement information on clinicaltrials.gov with additional, patient-focused information about the study, e.g., a study brochure and practical information on how to contact investigational sites. * A matching service, developed by Corengi, will compare Target Profiles to a de-dentified personally controlled health record (PCHR), represented by patient''''s Blue Button Plus CCDA XML document. * Integration into a patient community platform from Avado for providing the patient PCHR and presenting the results of the match service. The patient will be able to explore the respective matching studies for additional information and next steps such as contacting a nearby investigator clinic or hospital. The first demo of the prototype was made available on June 2014, built on a database of anonymized patient health records from different clinical research studies sponsored by Lilly, Novartis, and Pfizer. Other website: http://portal.lillycoi.com/ | drug development, tool development, clinical trial, clinical, patient profile, clinical research study, health record, platform, database |
uses: ClinicalTrials.gov is listed by: Consortia-pedia is related to: Pfizer Animal Genetics is related to: Corengi |
Open unspecified license, Public | nlx_158205 | SCR_003877 | SciCrunch Registry | p2t consortium | 2026-09-26 02:13:37 | 0 |
Can't find your Tool?
We recommend that you click next to the search bar to check some helpful tips on searches and refine your search firstly. Alternatively, please register your tool with the SciCrunch Registry by adding a little information to a web form, logging in will enable users to create a provisional RRID, but it not required to submit.
Welcome to the dkNET Resources search. From here you can search through a compilation of resources used by dkNET and see how data is organized within our community.
You are currently on the Community Resources tab looking through categories and sources that dkNET has compiled. You can navigate through those categories from here or change to a different tab to execute your search through. Each tab gives a different perspective on data.
If you have an account on dkNET then you can log in from here to get additional features in dkNET such as Collections, Saved Searches, and managing Resources.
Here is the search term that is being executed, you can type in anything you want to search for. Some tips to help searching:
If you are logged into dkNET you can add data records to your collections to create custom spreadsheets across multiple sources of data.
Here are the facets that you can filter the data by.
If you have any further questions please check out our FAQs Page to ask questions and see our tutorials. Click this button to view this tutorial again.
The NIDDK Information Network (dkNET) serves the needs of basic and clinical investigators by providing seamless access to large pools of data and research resources relevant to the mission of The National Institute of Diabetes Digestive and Kidney Diseases (NIDDK). dkNET is hosted at University of California San Diego, and is supported by NIH NIDDK grant U24DK097771.
Email: info_at_ dknet.org
